AzTrials
AzTrials

Cow Milk AllergyNCT02785679

The Influence of Early and Continuous Exposure of Infants to Cow's Milk Formula on the Prevention of Milk Allergy

A study testing cow's milk formula in people with Cow Milk Allergy and Newborns, run by Meir Medical Center at 1 site in Israel.

Unknown status

Status not confirmed. The sponsor has not verified this record for over two years, so it may be out of date.

Official record
Search all trials

Trial summary

Cow's milk protein (CMP) allergy is one of the most common food allergies and potentially a fatal one. Early feeding with CMP has been considered in the past as a risk factor for development of CMP allergy in high risk infants. Read more about this study

Who is it for?
Ages 2 hours to 2 daysHealthy volunteers can take part
Conditions the study is for
Cow Milk Allergy, Newborns
What is being tested?
cow's milk formula
Could I receive a placebo?
No, everyone receives an active treatment
How many people
2,500 participants
Where
1 siteIsrael
Study dates
20 Mar 2018to 31 Dec 2021
Phase
Interventional
Are there results?
None posted in the registry

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 2 hours to 2 days
  • All sexes
  • Healthy volunteers accepted
  • Child

Who may be able to join

  • Term and near term newborns (gestational age of at least 36 weeks)
  • normal birth weight
  • normal perinatal follow-up (physiological neonatal jaundice is not an exclusion criteria)
  • without congenital defects

Who cannot join

  • Preterm newborns
  • Congenital defects
  • Newborn suffering from acute event

Trial locations and contacts

1 site in 1 country.

Idit Lachover- Roth, MD contact

972-9-7472320

idit.roth@clalit.org.il

Israel1 site, 1 recruiting
  • Meir medical center

    Kfar Saba

    Idit Lachover - Roth, MD, 972-54-3152585, idit.roth@clalit.org.il

    Recruiting

Other trials in Israel

About this study

Cow's milk protein (CMP) allergy is one of the most common food allergies and potentially a fatal one. Early feeding with CMP has been considered in the past as a risk factor for development of CMP allergy in high risk infants. Although other studies argue with this assumption and suggest early exposure to CMP might be protective against atopic dermatitis and CMP allergy. A cohort study that first introduction of CMP after 15-30 days of age, raised the risk for CMP allergy.The aim of this study is to investigate if early and continuous exposure to CMF will decrease CMP allergy rate.

Read the detailed description

Background: Cow's milk protein (CMP) allergy is one of the most common food allergies and potentially a fatal one. The incidence of milk allergy is 1.5-3% in the first year of life, but only 60% of the reactions are IgE mediated. CMP allergy tends to resolve in approximately 45-50% of the infants at 1 year of age, in 60-75% at the age of 2, and 85-90% at 3 years. The range for IgE mediated CMP allergy is 29-76%. A recent study suggested that the natural history of CMP allergy might have changed over time, with slower rates of resolution and a higher proportion of children with disease persisting into adolescence and adulthood. In the past it has been described that there is more incidence of CMP allergy in children from families with positive history of allergy. Early feeding with CMP has been considered in the past as a risk factor for development of CMP allergy in high risk infants. Although other studies argue with this assumption and suggest early exposure to CMP might be protective against atopic dermatitis and CMP allergy. A cohort study that first introduction of CMP after 15-30 days of age, raised the risk for CMP allergy. A recent study on peanut allergy found that continuous early exposure to peanut dramatically decreased the incidence of peanut allergy. The research in the field of food allergy and especially in CMP allergy is very alert those days. But as far as the investigators knowledge, there are no prospective studies from the first days of life that examined the influence of early and continuous exposure to cow's milk formula (CMF) on CMP allergy. The existing data related to CMP allergy is controversial and inconclusive. Thus, no one can rely on it to establish clear recommendations for parents when is the best time to combine CMF in the infants diet. Working hypothesis and aims: The aim of the study is to investigate if early and continuous exposure to CMF will decrease CMP allergy rate. The investigators assumption is that the rate of CMP allergy in the intervention groups and in infants who are only feed by CMF, will be lower than in the group of infants who are exclusively breast feed. Methods: Recruitment of 2,500 infants from first day of life and divide the participants into 4 groups: 1. Exclusive breast feeding. 2. Exclusive CMF feeding. 3. Breast feeding with 20 cc of CMF per day. 4. Breast feeding with one meal per day of CMF. The mother will complete a survey questionnaire before the labor. Infants will be followed for 1 year. During this follow-up period -the participants will be examined by an allergologist at the age of 2 month and 1 year. In between, the infants will be followed by a phone questionnaire once in a month. Specific CM IgE analysis from umbilical cord blood and skin test at 2 month of age will be performed. Inclusion criteria - Term and near term newborns (gestational age of at least 36 weeks), normal birth weight, normal perinatal follow-up and without congenital defects. Expected results: The rate of CMP allergy in the intervention groups and in the group on exclusively CMF feeding will be lower than in the group on exclusive breast feeding. Importance: If the investigators will be able to prove the study hypothesis (and even if not), it will have a significant influence on the diet recommendations for infants. Probable implications to Medicine: If the investigators will get the expected results, the recommendations that exist today for infant's feeding can be changed.

Being tested
cow's milk formula
Keywords
Allergy, Cow's milk, breast feeding, Cow's milk formula, prevention
Medical subject headings
Milk Hypersensitivity, Hypersensitivity, Breast Feeding

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • cow's milk formulaDietary supplement

    addition of cow's milk formula in two different dosage - one only 20ml per day and one group a full meal per day

Study groups in NCT02785679
Study groupRoleWhat they receive
Exclusive breast feedingNo interventionExclusive breast feeding
Exclusive CMF feedingNo interventionExclusive CMF feeding
Breast feeding with small amount of CMFActive comparatorBreast feeding with addition (as intervention) of 20 cc of cow's milk formula (CMF) per day
Receives: Dietary Supplement: cow's milk formula
Breast feeding with one meal of CMFActive comparatorBreast feeding with addition (as intervention) of one meal per day of cow's milk formula (CMF)
Receives: Dietary Supplement: cow's milk formula

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. The incidence of cow's milk allergy in the intervention groups

    Measure the rate of cow's milk allergy infants in each group and compare the rate of allergy between the groups.

    Measured: 1 year

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted30 May 2016 (estimated)
  2. Study start20 Mar 2018
  3. Primary completion31 Aug 2021 (estimated)
  4. Study completion31 Dec 2021 (estimated)

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Interventional
Phase
Phase N/A
Primary purpose
Prevention
Allocation
Non-randomised
Intervention model
Parallel groups
Masking
None (open label)
Enrolment
2,500 participants (estimated)
IDs, dates and publications
ClinicalTrials.gov ID
NCT02785679
Sponsor's protocol ID
011-16-MMC
Status last verified
Apr 2021
First submitted
25 May 2016
Last updated
14 Apr 2021
Results posted
No
Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No

Publications

  • Lachover-Roth I, Cohen-Engler A, Furman Y, Rosman Y, Meir-Shafrir K, Mozer-Mandel M, Farladansky-Gershnabel S, Biron-Shental T, Confino-Cohen R. Infants born during COVID-19 pandemic experience increased susceptibility to airway hyperresponsiveness. Front Allergy. 2024 Dec 16;5:1512182. doi: 10.3389/falgy.2024.1512182. eCollection 2024.

    PubMed 39737062
  • Lachover-Roth I, Cohen-Engler A, Furman Y, Rosman Y, Meir-Shafrir K, Mozer-Mandel M, Farladansky-Gershnabel S, Biron-Shental T, Confino-Cohen R. Food allergy and infant feeding practices: Are they related? Ann Allergy Asthma Immunol. 2023 Sep;131(3):369-375.e3. doi: 10.1016/j.anai.2023.05.031. Epub 2023 Jun 1.

    PubMed 37270027

Questions about this trial

What is this clinical trial studying?

A study testing cow's milk formula in people with Cow Milk Allergy and Newborns, run by Meir Medical Center at 1 site in Israel.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 4 inclusion and 3 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: status not confirmed, as of the sponsor's last update on 14 Apr 2021. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 1 site in Israel. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

Are results available for this study?

Results are not available in the source record.

How can a doctor refer a patient or contact the research team?

Contact Idit Lachover- Roth, MD (972-9-7472320, idit.roth@clalit.org.il), or a site near the patient. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

The incidence of cow's milk allergy in the intervention groups (time frame: 1 year). It is what the study was designed to measure, not a finding.

Where can I read the original study information?

On the ClinicalTrials.gov record for NCT02785679, which also lists 2 linked publications.

Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 14 Apr 2021.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in